Correlation Between ESSA Pharma and Rapport Therapeutics,

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both ESSA Pharma and Rapport Therapeutics, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining ESSA Pharma and Rapport Therapeutics, into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between ESSA Pharma and Rapport Therapeutics, Common, you can compare the effects of market volatilities on ESSA Pharma and Rapport Therapeutics, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in ESSA Pharma with a short position of Rapport Therapeutics,. Check out your portfolio center. Please also check ongoing floating volatility patterns of ESSA Pharma and Rapport Therapeutics,.

Diversification Opportunities for ESSA Pharma and Rapport Therapeutics,

-0.21
  Correlation Coefficient

Very good diversification

The 3 months correlation between ESSA and Rapport is -0.21. Overlapping area represents the amount of risk that can be diversified away by holding ESSA Pharma and Rapport Therapeutics, Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Rapport Therapeutics, and ESSA Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on ESSA Pharma are associated (or correlated) with Rapport Therapeutics,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Rapport Therapeutics, has no effect on the direction of ESSA Pharma i.e., ESSA Pharma and Rapport Therapeutics, go up and down completely randomly.

Pair Corralation between ESSA Pharma and Rapport Therapeutics,

Given the investment horizon of 90 days ESSA Pharma is expected to generate 0.37 times more return on investment than Rapport Therapeutics,. However, ESSA Pharma is 2.68 times less risky than Rapport Therapeutics,. It trades about -0.12 of its potential returns per unit of risk. Rapport Therapeutics, Common is currently generating about -0.22 per unit of risk. If you would invest  179.00  in ESSA Pharma on September 12, 2024 and sell it today you would lose (10.00) from holding ESSA Pharma or give up 5.59% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

ESSA Pharma  vs.  Rapport Therapeutics, Common

 Performance 
       Timeline  
ESSA Pharma 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days ESSA Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's forward indicators remain fairly strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.
Rapport Therapeutics, 

Risk-Adjusted Performance

3 of 100

 
Weak
 
Strong
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Rapport Therapeutics, Common are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. Even with relatively abnormal basic indicators, Rapport Therapeutics, reported solid returns over the last few months and may actually be approaching a breakup point.

ESSA Pharma and Rapport Therapeutics, Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with ESSA Pharma and Rapport Therapeutics,

The main advantage of trading using opposite ESSA Pharma and Rapport Therapeutics, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if ESSA Pharma position performs unexpectedly, Rapport Therapeutics, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Rapport Therapeutics, will offset losses from the drop in Rapport Therapeutics,'s long position.
The idea behind ESSA Pharma and Rapport Therapeutics, Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.

Other Complementary Tools

USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Equity Valuation
Check real value of public entities based on technical and fundamental data
Share Portfolio
Track or share privately all of your investments from the convenience of any device